AKEBIA THERAPEUTICS INC (AKBA) Stock Fundamental Analysis
USA - NASDAQ:AKBA - US00972D1054 - Common Stock
1.85 USD
+0.04 (+2.21%)
1.88 USD
+0.03 (+1.62%)
Overall AKBA gets a fundamental rating of 3 out of 10. We evaluated AKBA against 531 industry peers in the Biotechnology industry. AKBA has a medium profitability rating, but doesn't score so well on its financial health evaluation. AKBA is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
AKBA had negative earnings in the past year.
AKBA had a negative operating cash flow in the past year.
In the past 5 years AKBA always reported negative net income.
In the past 5 years AKBA always reported negative operating cash flow.
1.2 Ratios
AKBA has a Return On Assets of -10.56%. This is amongst the best in the industry. AKBA outperforms 83.62% of its industry peers.
Looking at the Return On Equity, with a value of -124.84%, AKBA is in line with its industry, outperforming 40.30% of the companies in the same industry.
With an excellent Return On Invested Capital value of 1.39%, AKBA belongs to the best of the industry, outperforming 89.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.56% | ||
| ROE | -124.84% | ||
| ROIC | 1.39% |
ROA(3y)-26.46%
ROA(5y)-38.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AKBA has a Operating Margin of 1.96%. This is amongst the best in the industry. AKBA outperforms 89.64% of its industry peers.
With an excellent Gross Margin value of 83.22%, AKBA belongs to the best of the industry, outperforming 86.06% of the companies in the same industry.
In the last couple of years the Gross Margin of AKBA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.96% | ||
| PM (TTM) | N/A | ||
| GM | 83.22% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.75%
GM growth 5Y4.73%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so AKBA is destroying value.
The number of shares outstanding for AKBA has been increased compared to 1 year ago.
The number of shares outstanding for AKBA has been increased compared to 5 years ago.
AKBA has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -4.81, we must say that AKBA is in the distress zone and has some risk of bankruptcy.
AKBA's Altman-Z score of -4.81 is in line compared to the rest of the industry. AKBA outperforms 40.30% of its industry peers.
AKBA has a Debt/Equity ratio of 6.07. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 6.07, AKBA is not doing good in the industry: 83.24% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 6.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.81 |
ROIC/WACC0.18
WACC7.91%
2.3 Liquidity
AKBA has a Current Ratio of 1.98. This is a normal value and indicates that AKBA is financially healthy and should not expect problems in meeting its short term obligations.
AKBA has a Current ratio of 1.98. This is in the lower half of the industry: AKBA underperforms 75.71% of its industry peers.
A Quick Ratio of 1.84 indicates that AKBA should not have too much problems paying its short term obligations.
AKBA has a Quick ratio of 1.84. This is in the lower half of the industry: AKBA underperforms 76.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.98 | ||
| Quick Ratio | 1.84 |
3. Growth
3.1 Past
AKBA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 69.57%, which is quite impressive.
Looking at the last year, AKBA shows a very negative growth in Revenue. The Revenue has decreased by -17.70% in the last year.
Measured over the past years, AKBA shows a very negative growth in Revenue. The Revenue has been decreasing by -13.72% on average per year.
EPS 1Y (TTM)69.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)-17.7%
Revenue growth 3Y-8.88%
Revenue growth 5Y-13.72%
Sales Q2Q%57.02%
3.2 Future
Based on estimates for the next years, AKBA will show a very strong growth in Earnings Per Share. The EPS will grow by 28.81% on average per year.
The Revenue is expected to grow by 23.71% on average over the next years. This is a very strong growth
EPS Next Y99.23%
EPS Next 2Y58.53%
EPS Next 3Y40.83%
EPS Next 5Y28.81%
Revenue Next Year59.48%
Revenue Next 2Y44.28%
Revenue Next 3Y27.26%
Revenue Next 5Y23.71%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
AKBA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 10.93, which indicates a very decent valuation of AKBA.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AKBA indicates a rather cheap valuation: AKBA is cheaper than 97.36% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 34.43. AKBA is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 10.93 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AKBA indicates a rather cheap valuation: AKBA is cheaper than 93.22% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 23.16 |
4.3 Compensation for Growth
AKBA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AKBA's earnings are expected to grow with 40.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.53%
EPS Next 3Y40.83%
5. Dividend
5.1 Amount
AKBA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.85
+0.04 (+2.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners41.13%
Inst Owner Change1.26%
Ins Owners3.57%
Ins Owner Change1.4%
Market Cap490.53M
Revenue(TTM)160.18M
Net Income(TTM)-36.48M
Analysts87.27
Price Target7.55 (308.11%)
Short Float %11.73%
Short Ratio8.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)132.68%
Min EPS beat(2)100%
Max EPS beat(2)165.36%
EPS beat(4)2
Avg EPS beat(4)47%
Min EPS beat(4)-54.81%
Max EPS beat(4)165.36%
EPS beat(8)5
Avg EPS beat(8)38.39%
EPS beat(12)7
Avg EPS beat(12)14.69%
EPS beat(16)8
Avg EPS beat(16)19.03%
Revenue beat(2)2
Avg Revenue beat(2)27.45%
Min Revenue beat(2)25.24%
Max Revenue beat(2)29.66%
Revenue beat(4)3
Avg Revenue beat(4)14.85%
Min Revenue beat(4)-17.55%
Max Revenue beat(4)29.66%
Revenue beat(8)3
Avg Revenue beat(8)0.04%
Revenue beat(12)5
Avg Revenue beat(12)-0.56%
Revenue beat(16)8
Avg Revenue beat(16)11.67%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)37.5%
EPS NQ rev (3m)45.31%
EPS NY rev (1m)88.64%
EPS NY rev (3m)96.09%
Revenue NQ rev (1m)11.86%
Revenue NQ rev (3m)24.87%
Revenue NY rev (1m)6.58%
Revenue NY rev (3m)19.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 10.93 | ||
| P/S | 2.41 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 16.79 | ||
| P/tB | N/A | ||
| EV/EBITDA | 23.16 |
EPS(TTM)-0.07
EYN/A
EPS(NY)0.17
Fwd EY9.15%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.77
BVpS0.11
TBVpS-0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.56% | ||
| ROE | -124.84% | ||
| ROCE | 1.76% | ||
| ROIC | 1.39% | ||
| ROICexc | 3.52% | ||
| ROICexgc | 10.33% | ||
| OM | 1.96% | ||
| PM (TTM) | N/A | ||
| GM | 83.22% | ||
| FCFM | N/A |
ROA(3y)-26.46%
ROA(5y)-38.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.75%
GM growth 5Y4.73%
F-Score4
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 6.07 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 7.6 | ||
| Cap/Depr | 0.76% | ||
| Cap/Sales | 0.07% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.98 | ||
| Quick Ratio | 1.84 | ||
| Altman-Z | -4.81 |
F-Score4
WACC7.91%
ROIC/WACC0.18
Cap/Depr(3y)0.13%
Cap/Depr(5y)0.3%
Cap/Sales(3y)0.02%
Cap/Sales(5y)0.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y99.23%
EPS Next 2Y58.53%
EPS Next 3Y40.83%
EPS Next 5Y28.81%
Revenue 1Y (TTM)-17.7%
Revenue growth 3Y-8.88%
Revenue growth 5Y-13.72%
Sales Q2Q%57.02%
Revenue Next Year59.48%
Revenue Next 2Y44.28%
Revenue Next 3Y27.26%
Revenue Next 5Y23.71%
EBIT growth 1Y111.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y92.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y93.09%
OCF growth 3YN/A
OCF growth 5YN/A
AKEBIA THERAPEUTICS INC / AKBA FAQ
What is the fundamental rating for AKBA stock?
ChartMill assigns a fundamental rating of 3 / 10 to AKBA.
Can you provide the valuation status for AKEBIA THERAPEUTICS INC?
ChartMill assigns a valuation rating of 5 / 10 to AKEBIA THERAPEUTICS INC (AKBA). This can be considered as Fairly Valued.
How profitable is AKEBIA THERAPEUTICS INC (AKBA) stock?
AKEBIA THERAPEUTICS INC (AKBA) has a profitability rating of 4 / 10.
Can you provide the financial health for AKBA stock?
The financial health rating of AKEBIA THERAPEUTICS INC (AKBA) is 1 / 10.